HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $32 to $45.
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $32 to $45.